The robust U.S. IPO pipeline in late 2026 reflects strong equity issuance momentum, with 255 offerings completed year-to-date through mid-October amid elevated capital needs tied to AI infrastructure spending. Recent pricings, including Iambic Therapeutics’ $150 million debut on October 15 and multiple SPAC and biotech listings, underscore sustained market access despite 10-year Treasury yields near 5.3% and a Federal Reserve rate path that has tempered broader sentiment. Goldman Sachs projects $175 billion in 2027 IPO volume following a record $675 billion in total equity issuance for 2026, driven by follow-on activity and mega-cap readiness. Key near-term catalysts include potential Anthropic and other AI-related filings that could clear before year-end, alongside seasonal earnings data and any further policy signals affecting risk appetite and valuation multiples.
This market will resolve to "Yes" if the listed company completes an Initial Public Offering (IPO) by December 31, 2026, 11:59 PM ET, as confirmed by official company announcements or credible news sources. The IPO refers to the first sale of stock by the listed company to the public on any recognized stock exchange. If the listed company merges with another entity, is acquired, or ceases to exist before the market resolves, the market will also resolve to "No". This market will resolve early if the listed company completes an IPO by December 31, 2026, 11:59 PM ET. The resolution source for this market is a consensus of credible reporting.